Michael Rapp - Insider Trading Tracker

Immunome, Inc.

US ˙ NasdaqCM ˙ US45257U1088

Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael Rapp. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders

Companies with Reported Insider Positions

The SEC filings indicate Michael Rapp has reported holdings or trades in the following companies:

Security	Title	Latest Reported Holdings
US:IMNM / Immunome, Inc.	Director	1,071,172
US:ZYNE / Zynerba Pharmaceuticals Inc	10% Owner	1,500,000
US:STKS / The ONE Group Hospitality, Inc.	Director	1,563,198

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael Rapp. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases IMNM / Immunome, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IMNM / Immunome, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2021-09-13	IMNM	RAPP MICHAEL	25,962	19.9600	25,962	19.9600	518,202	11	27.7000	200,946	38.78
2021-09-10	IMNM	RAPP MICHAEL	15,500	17.8500	15,500	17.8500	276,675
2021-09-09	IMNM	RAPP MICHAEL	8,170	17.4400	8,170	17.4400	142,485
2021-09-09	IMNM	RAPP MICHAEL	22,280	18.4600	22,280	18.4600	411,289
2021-05-26	IMNM	RAPP MICHAEL	2,300	18.9400	2,300	18.9400	43,562
2021-05-25	IMNM	RAPP MICHAEL	19,303	18.3200	19,303	18.3200	353,631
2021-05-24	IMNM	RAPP MICHAEL	31,895	18.3800	31,895	18.3800	586,230
2020-10-06	IMNM	RAPP MICHAEL	83,332	12.0000	83,332	12.0000	999,984

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Sales IMNM / Immunome, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IMNM / Immunome, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Purchases STKS / The ONE Group Hospitality, Inc. - Short Term Profit Analysis

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2013-10-16	CCAC	RAPP MICHAEL	163,056	5.0000	163,056	5.0000	815,280	730	3.57	-233,170	-28.60
2012-03-01	CCAC	RAPP MICHAEL	10,214		10,214

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

STKS / The ONE Group Hospitality, Inc. Insider Trades

Insider Sales STKS / The ONE Group Hospitality, Inc. - Short Term Loss Analysis

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2012-03-01	CCAC	RAPP MICHAEL	100,000		100,000			730

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Trading History

This table shows the complete list of insider trades made by Michael Rapp as disclosed to the Securities Exchange Commission (SEC).

File Date	Tran Date	Form	Ticker	Security	Code	Shares	Remaining Shares	Percent Change	Share Price	Tran Value	Remaining Value
2023-10-03	2023-10-02	4	IMNM	Immunome Inc. Common Stock	A - Award	253,806	1,071,172	31.05	5.91	1,499,993	6,330,627
2023-01-17	2023-01-15	4	IMNM	Immunome Inc. Common Stock	A - Award	17,500	817,366	2.19	4.00	70,000	3,269,464
2021-09-14	2021-09-13	4	IMNM	Immunome Inc. Common Stock	P - Purchase	25,962	208,742	14.20	19.96	518,202	4,166,490
2021-09-13	2021-09-10	4	IMNM	Immunome Inc. Common Stock	P - Purchase	15,500	182,780	9.27	17.85	276,675	3,262,623
2021-09-13	2021-09-09	4	IMNM	Immunome Inc. Common Stock	P - Purchase	22,280	167,280	15.37	18.46	411,289	3,087,989
2021-09-13	2021-09-09	4	IMNM	Immunome Inc. Common Stock	P - Purchase	8,170	145,000	5.97	17.44	142,485	2,528,800
2021-06-01	2021-05-28	4	IMNM	Immunome Inc. Stock Option (Right to Buy)	A - Award	3,750	3,750
2021-05-26	2021-05-26	4	IMNM	Immunome Inc. Common Stock	P - Purchase	2,300	136,830	1.71	18.94	43,562	2,591,560
2021-05-26	2021-05-25	4	IMNM	Immunome Inc. Common Stock	P - Purchase	19,303	134,530	16.75	18.32	353,631	2,464,590
2021-05-26	2021-05-24	4	IMNM	Immunome Inc. Common Stock	P - Purchase	31,895	115,227	38.27	18.38	586,230	2,117,872
2020-11-05	2020-11-03	4	IMNM	Immunome Inc. Stock Option (Right to Buy)	A - Award	7,500	7,500
2020-10-08	2020-10-06	4	IMNM	Immunome Inc. Warrant (right to buy)	C - Conversion	166,666	166,666
2020-10-08	2020-10-06	4	IMNM	Immunome Inc. Warrant (right to buy)	C - Conversion	-166,666	0	-100.00
2020-10-08	2020-10-06	4	IMNM	Immunome Inc. Series A Convertible Preferred Stock	C - Conversion	-555,554	0	-100.00
2020-10-08	2020-10-06	4	IMNM	Immunome Inc. Common Stock	P - Purchase	83,332	638,886	15.00	12.00	999,984	7,666,632
2020-10-08	2020-10-06	4	IMNM	Immunome Inc. Common Stock	C - Conversion	555,554	555,554
2020-10-01		3	IMNM	Immunome Inc. Common Stock			827,640
2018-05-31	2018-05-30	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	P - Purchase	5,885	1,500,000	0.39	10.45	61,498	15,675,000
2018-05-02	2018-05-02	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	P - Purchase	15,000	1,494,115	1.01	10.46	156,945	15,632,925
2018-03-23	2018-03-22	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	P - Purchase	10,000	1,479,115	0.68	9.28	92,790	13,724,708
2018-01-03	2018-01-02	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	P - Purchase	15,000	1,469,115	1.03	12.99	194,847	19,083,510
2017-10-23	2017-10-23	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	P - Purchase	25,745	1,454,115	1.80	9.94	255,795	14,447,650
2017-10-23	2017-10-20	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	P - Purchase	30,000	1,428,370	2.15	9.78	293,538	13,976,029
2017-10-23	2017-10-19	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	P - Purchase	44,255	1,398,370	3.27	9.59	424,405	13,410,368
2016-12-29	2016-12-29	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	P - Purchase	10,000	1,354,115	0.74	15.85	158,500	21,462,723
2016-02-16	2016-02-02	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	J - Other	80,467	1,344,115	6.37
2015-08-10	2015-08-10	4	ZYNE	Zynerba Pharmaceuticals, Inc. Series 1 Convertible Preferred Stock	C - Conversion	-1,066,911	0	-100.00
2015-08-10	2015-08-10	4	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock	C - Conversion	567,505	1,263,648	81.52
2015-08-04		3	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock			2,040,258
2015-08-04		3	ZYNE	Zynerba Pharmaceuticals, Inc. Series 1 Convertible Preferred Stock			1,911,620
2015-08-04		3	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock			1,424,582
2015-08-04		3	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock			2,040,258
2015-08-04		3	ZYNE	Zynerba Pharmaceuticals, Inc. Series 1 Convertible Preferred Stock			1,911,620
2015-08-04		3	ZYNE	Zynerba Pharmaceuticals, Inc. Common Stock			1,424,582
2013-10-18	2013-10-16	4	CCAC	COMMITTED CAPITAL ACQUISITION Corp Common Stock, par value $0.0001 per share	P - Purchase	163,056	1,563,198	11.65	5.00	815,280	7,815,990
2013-04-25	2013-04-23	4	CCAC	COMMITTED CAPITAL ACQUISITION Corp Common Stock, par value $0.0001 per share	J - Other	-121,500	1,564,199	-7.21
2013-04-25	2013-04-23	4	CCAC	COMMITTED CAPITAL ACQUISITION Corp Common Stock, par value $0.0001 per share	J - Other	-75,750	1,685,699	-4.30
2012-06-20	2012-06-19	4	CCAC	COMMITTED CAPITAL ACQUISITION Corp Common Stock, par value $0.0001 per share	J - Other	93,250	1,761,449	5.59
2012-06-20	2012-06-19	4	CCAC	COMMITTED CAPITAL ACQUISITION Corp Common Stock, par value $0.0001 per share	J - Other	-176,000	1,668,199	-9.54
2012-03-05	2012-03-01	4	CCAC	COMMITTED CAPITAL ACQUISITION Corp Common Stock, par value $0.0001 per share	P - Purchase	10,214	1,844,199	0.56
2012-03-05	2012-03-01	4	CCAC	COMMITTED CAPITAL ACQUISITION Corp Common Stock, par value $0.0001 per share	S - Sale	-100,000	1,833,985	-5.17

Open market or private purchase of non-derivative or derivative security

Open market or private sale of non-derivative or derivative security

Grant, award, or other acquisition of securities from the company (such as an option)

Conversion of derivative

Sale or transfer of securities back to the company

Payment of exercise price or tax liability using portion of securities received from the company

Gift of securities by or to the insider

Equity swaps and similar hedging transactions

Exercise or conversion of derivative security received from the company (such as an option)

A transaction voluntarily reported on Form 4

Other (accompanied by a footnote describing the transaction)